0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

ISONIAZID THERAPY IN CUTANEOUS TUBERCULOSIS AND SARCOIDOSIS

Robert E. Holsinger, M.D.; John Eric Dalton, M.D.
JAMA. 1954;154(6):475-481. doi:10.1001/jama.1954.02940400013004.
Text Size: A A A
Published online

ABSTRACT

The rather unsatisfactory results of previous therapies in cutaneous tuberculosis led us to investigate the newer agents introduced for the treatment of this disease in other organs. Because tuberculoderms are uncommon, it is difficult to assemble individually any large series of such cases for an evaluation of their curative plans. Thus, for our guidance, we turned to the larger therapeutic studies done on the more prevalent pulmonary forms of this malady, and we selected isoniazid for trial. Since sarcoidosis presents clinical and histopathological findings similar to tuberculosis and since it is also difficult to handle, we included two cases of this somewhat rare entity in this study.

NEWER ANTITUBERCULOUS AGENTS  The recent Veterans Administration, Army, and Navy Conference on Chemotherapy in Tuberculosis1 contributed much to our better understanding of the newer antituberculous agents. This group seems agreed that amithiozone (Tibione)1a is too toxic to warrant further employment. This

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

* * SCHEDULED MAINTENANCE * *

Our websites may be periodically unavailable between midnight and 04:00 ET Thursday, July 10th, for regularly scheduled maintenance.

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();